NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Traws Pharma, Inc. TRAW
15 fiscal years on record · USD · FY2025 reported · SEC filings only
Growth
USD 2.8M
Revenue, FY2025 · full 15-year series below
Revenue $M
Net income $M
FY2025 · Revenue 2.8 · Net income 9.2
Compound annual growth
Revenue compounded at +64.6% a year over five years.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
329 cents
of every revenue dollar became profit
Operating margin
Net margin
FY2025 · Operating -640.7% · Net 328.7%
ROE
FY2020 · ROE -217.4%
The 15-year record
15 fiscal years
Every figure from documents filed with the SEC · USD
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
row low → row highnegative
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Operating income $B | −0.0 | −0.1 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.1 | −0.1 | −0.0 | −0.0 |
| EBITDA $B | −0.0 | −0.1 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.1 | −0.1 | −0.0 | −0.0 |
| Income tax $B | · | · | · | · | · | 0.0 | 0.0 | −0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | · | · |
| Net income $B | 0.0 | −0.2 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.1 | −0.1 | −0.0 | −0.0 |
| Free cash flow $B | −0.0 | −0.0 | −0.0 | · | · | −0.0 | −0.0 | · | · | · | · | −0.1 | −0.1 | 0.0 | −0.0 |
| EPS, diluted $ | 0.82 | −35.21 | −22.57 | −0.91 | −0.96 | −2.17 | −1.49 | −4.99 | −40.15 | −4.44 | −10.54 | −2.94 | −6.12 | −15.35 | −14.18 |
| Dividend / sh $ | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
| ROE % | · | · | · | · | · | −217.4 | −253.6 | · | · | −274.9 | −146.4 | −123.5 | · | · | · |
| Shares out B | 0.01 | 0.00 | 0.00 | 0.02 | 0.02 | 0.01 | 0.11 | 0.01 | 0.00 | 0.01 | 0.00 | 0.02 | 0.02 | 0.00 | · |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 0 failures in 58 reconciliationsAUDITED
Reconciled in 15 of 19 fiscal years. 18 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2011